EUVIMEDEUVIMED entdecken
Crossref

3D Printing Polycaprolactone‐Gelatin for Musculoskeletal Tissue Engineering

Elaine Lui, Masanori Kobayashi, Charu Jain iD, Hirotsugu Maekawa, Jiannan Li, Seyedsina Moeinzadeh, Anthony An-Fa Dahm Chen iD, Weston Allen-Hicks, Benjamin Levi, Shuichi Matsuda, Toshiyuki Kawai iD, Yunzhi Peter Yang

Journal of Biomedical Materials Research Part A · 2026-03 · 114 (3)

DOI: 10.1002/jbm.a.70051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biomedical Materials Research Part A, online erschienen am 18.02.2026. Verfasst von Elaine Lui und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mechanical Engineering, Stanford University, Stanford, California, USA. Hauptthemen laut MEDLINE: Gelatin, Polyesters, Printing, Three-Dimensional, Tissue Engineering. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: NIH HHS, U.S. Department of Defense, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In musculoskeletal tissue engineering, there is a need for bone implants that are biocompatible, resorbable, promote tissue regeneration, and degrade at a rate matching healing. Polycaprolactone (PCL), an FDA‐approved biodegradable and bioinert polymer, can be functionalized with natural components without harsh crosslinking. This study presents the first demonstration of a homogeneous bulk polycaprolactone‐gelatin (PCL‐gelatin, PG) composite containing self‐assembled gelatin nanoparticles that retain bioactivity despite thermal processing for 3D printing applications. PG composites with varying gelatin content (10%, 20%, and 30%) and β‐tricalcium phosphate incorporation were fabricated through casting and melt processing into printable filaments at 110°C. Comprehensive characterization using mechanical testing, contact angle measurements, FTIR, TGA, EDS, and SEM confirmed homogeneous gelatin distribution as nanoscale particles throughout the PCL matrix, with systematic increases in hydrophilicity and enhanced mechanical properties proportional to gelatin content. Accelerated degradation studies revealed tunable degradation rates correlated with gelatin concentration, while in vitro studies with human mesenchymal stem cells demonstrated enhanced proliferation and early osteogenic differentiation markers, particularly in PG30 compositions. Subcutaneous implantation in rats over 24 weeks showed biocompatibility comparable to PCL with minimal inflammatory response and biphasic degradation behavior characterized by initial swelling followed by controlled volume reduction. In critical‐size femoral defects, PG30 exhibited superior early mechanical properties and increased preosteoblast density at bone interfaces compared to PCL and PCL‐TCP controls at 4 weeks. This developed fabrication methodology enables precise spatial control through 3D printing while preserving gelatin bioactivity. This approach offers a promising advancement for tissue engineering applications requiring enhanced cellular interactions and controlled degradation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GelatinPolyestersPrinting, Three-DimensionalTissue EngineeringAnimalsHumansMesenchymal Stem CellsTissue ScaffoldsRatsRats, Sprague-DawleyOsteogenesisMaterials Testing

Stichwörter der Autor:innen

3D printingbioactive scaffoldsbone tissue engineeringcomposite biomaterialsgelatinpolycaprolactone

Substanzen

GelatinPolyesterspolycaprolactone

Autor:innen und Institutionen

  • Department of Mechanical Engineering, Stanford University, Stanford, California, USA.
  • Department of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, California, USA.
  • Department of Orthopedic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Center for Organogenesis and Trauma, Department of Surgery, University of Texas Southwestern, Dallas, Texas, USA.
  • Department of Materials Science and Engineering, Stanford University, Stanford, California, USA.
  • Department of Bioengineering, Stanford University, Stanford, California, USA.

ORCID-Profile: Charu Jain, Anthony An-Fa Dahm Chen, Toshiyuki Kawai

Förderung

  • NIH HHS
  • U.S. Department of Defense
  • National Institutes of Health

Zitieren

APA

Lui, E., Kobayashi, M., Jain, C., Maekawa, H., Li, J., Moeinzadeh, S., Chen, A. A. D., Allen-Hicks, W., Levi, B., Matsuda, S., Kawai, T., & Yang, Y. P. (2026). 3D Printing Polycaprolactone‐Gelatin for Musculoskeletal Tissue Engineering. Journal of Biomedical Materials Research Part A, 114(3). https://doi.org/10.1002/jbm.a.70051

Vancouver

Lui E, Kobayashi M, Jain C, Maekawa H, Li J, Moeinzadeh S, et al. 3D Printing Polycaprolactone‐Gelatin for Musculoskeletal Tissue Engineering. Journal of Biomedical Materials Research Part A. 2026;114(3). doi:10.1002/jbm.a.70051

BibTeX
@article{Lui2026,
  author = {Lui, Elaine and Kobayashi, Masanori and Jain, Charu and Maekawa, Hirotsugu and Li, Jiannan and Moeinzadeh, Seyedsina and Chen, Anthony An-Fa Dahm and Allen-Hicks, Weston and Levi, Benjamin and Matsuda, Shuichi and Kawai, Toshiyuki and Yang, Yunzhi Peter},
  title = {3D Printing Polycaprolactone‐Gelatin for Musculoskeletal Tissue Engineering},
  journal = {Journal of Biomedical Materials Research Part A},
  year = {2026},
  volume = {114},
  number = {3},
  doi = {10.1002/jbm.a.70051}
}
Kostenlos starten →